中信建投證券(06066.HK)發行40億元次級債券
格隆匯 3 月 19日丨中信建投證券(06066.HK)發佈公吿,中信建投證券股份有限公司2021年面向專業投資者公開發行次級債券(第二期)發行工作已於2021年3月19日結束,該期債券品種一(債券簡稱:21信投C3,代碼:175758)實際發行規模30億元,最終票面利率為3.40%,品種二(債券簡稱:21信投C4,代碼:175759)實際發行規模10億元,最終票面利率為3.88%。
其中,發行人依據《企業會計準則》確定的關聯方中信證券股份有限公司管理的產品參與該期債券認購,最終獲配品種一的金額為人民幣2.40億元,佔該期債券發行總規模的6.00%;中銀理財管理的產品參與該期債券認購,最終獲配品種二的金額為人民幣1.00億元,佔該期債券發行總規模的2.50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.